- Rating
- 1
- Confidence
- 4
- Informativeness
- 1
- Presentation
- 1
- Soundness
- 1
Read review
Paper summary
SID-MedRec tackles medication recommendation from longitudinal EHRs. It uses an RQ-VAE to turn BioBERT embeddings of diagnoses, procedures, and medications into hierarchical semantic IDs. Within each visit, a Set Transformer aggregates concepts; separate GRUs handle the temporal dimension across visits; and an adaptive DDI-aware loss trades off prescription accuracy against drug–drug interaction risk. Experiments compare against nine baselines on MIMIC-III and MIMIC-IV.
Critical strengths
- The separation of within-visit set modeling from across-visit temporal modeling fits EHRs' nested structure naturally. The ablation confirms the set encoder helps, and dropping the DDI loss pushes the DDI rate up on both datasets. Together, these support the visit-encoder design and the safety-aware training objective.
Critical weaknesses
- The case for SID as the core contribution is thin. Table 3 shows small and mixed effects from quantization, and no other measured outcome explains why the discrete representation is actually needed. Code utilization, complete-tuple collisions, and the relationship to SCQMed are largely left unaddressed. The Method section spends most of its space on standard components while giving too little room to these SID-specific design choices. In the end, I came away without a clear picture of what quantization is buying for medication recommendation.
- The safety claim is hard to evaluate at the reported operating point. The DDI-loss ablation shows a benefit, but the full model actually has both higher accuracy and higher DDI than SafeDrug. Ground-truth DDI rates and DDI_target values are missing, the difference from SafeDrug's control mechanism is not clearly explained, and the accuracy advantage at comparable DDI levels is not established. Some medication-recommendation methods discussed in the paper (MoleRec, COGNet, DrugDoctor) are also absent from the experiments. These gaps make it hard to assess the claimed accuracy–safety advantage.
AI-use disclosure. I could not find the required disclosure section in the manuscript or appendix.
Questions for authors
- What are the complete-tuple utilization and collision rates per modality? How does sharing an SID affect the model's ability to distinguish concepts?
- Given the small and mixed changes in Table 3, what concrete, measurable benefit does the discrete SID representation provide? Can you substantiate at least one — compactness, rare-concept performance, or something else?
- Does the w/o SID variant keep the same pretrained semantic embeddings and downstream architecture? What exactly does Table 3 isolate about quantization itself?
- What are the ground-truth prescription DDI rates and DDI_target values on both datasets, and how were the targets chosen?
- How should the sigmoid control be compared with SafeDrug's controllable loss — especially the design of keeping a nonzero DDI coefficient even at zero observed DDI? Does the accuracy advantage hold at comparable DDI levels?
- What distinguishes the SID representation from SCQMed's approach? For MoleRec, COGNet, and DrugDoctor — which are discussed in the paper — which comparisons apply here, and why were they left out?
I haven’t seen a response to my review. My two main concerns remain.
In my view, the paper falls well below the bar for acceptance at ICLR, and I remain skeptical of the method’s claimed benefits. I will not change my rating.